Pharma
Boehringer Ingelheim GmbH
5
Articles
Mentioned
Top Role
Jan 22, 2026
First Mention
Apr 7, 2026
Last Mention
1.89
Relevance Score
Coverage Timeline
April 2026
Novartis Spins Off Sandoz: What the $10B Pure-Play Means for Biosimilar Strategies and Drug Pricing 2025-2026
Deals
Competitor
Apr 7, 2026
Amgen, Viatris, Boehringer Ingelheim, they all have their sites set on Humira and Neulasta biosimilar shares.
February 2026
Late-Stage Obesity Drugs Beyond GLP-1s: Orforglipron, Survodutide, and the Oral Alternatives That Could Reshape Pricing
Pipeline
Mentioned
Feb 18, 2026
Boehringer Ingelheim’s survodutide, still injectable for now, recently delivered up to 19% weight loss in Phase 2 studies.
IRA Price Negotiation Year One: What the Numbers Reveal About CMS, Drugmakers, and the Real Deals
Policy
Mentioned
Feb 5, 2026
The reality: these drugs were uniquely vulnerable.
January 2026
Jan 27, 2026
Boehringer and Zealand are already planning a familiar playbook for pricing and market access.
IRA Price Negotiation Year One: Who Blinked, Who Balked, and What's Next for Big Ticket Drugs
Policy
Mentioned
Jan 22, 2026
Jardiance (Boehringer/Lilly) was among the list of drugs up for negotiation.